A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.

[1]  E. Nakakura,et al.  Pancreatic Adenocarcinoma, Version 1.2019. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  S. Choi,et al.  Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial , 2018, Annals of surgery.

[3]  M. Reni,et al.  Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma. , 2017 .

[4]  H. Zeh,et al.  Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes? , 2017, Annals of Surgical Oncology.

[5]  M. Reni,et al.  Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma , 2016, British Journal of Cancer.

[6]  T. Conroy,et al.  FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. , 2016, The Lancet. Oncology.

[7]  M. Besselink,et al.  Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer , 2016, Annals of Surgical Oncology.

[8]  P. Bachellier,et al.  Pancreatic Adenocarcinoma with Venous Involvement: Is Up-Front Synchronous Portal-Superior Mesenteric Vein Resection Still Justified? A Survey of the Association Française de Chirurgie , 2015, Annals of Surgical Oncology.

[9]  G. Varadhachary,et al.  Resectable, Borderline Resectable, and Locally Advanced Pancreatic Cancer: What Does It Matter? , 2014, Current Oncology Reports.

[10]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[11]  David Cella,et al.  Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[13]  Gang Li,et al.  Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. , 2011, Surgery.

[14]  Tibor Schuster,et al.  Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages , 2010, PLoS medicine.

[15]  G. Kazemier,et al.  Staging for locally advanced pancreatic cancer. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[16]  M. Reni,et al.  Carbohydrate antigen 19‐9 change during chemotherapy for advanced pancreatic adenocarcinoma , 2009, Cancer.

[17]  W. Hohenberger,et al.  Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised phase II-study of the Interdisciplinary Working Group Gastrointestinal Tumours (AIO, ARO , 2007, BMC Cancer.

[18]  M. Reni,et al.  Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. , 2005, The Lancet. Oncology.

[19]  T. Kubota,et al.  Docetaxel enhances the cytotoxicity of cisplatin to gastric cancer cells by modification of intracellular platinum metabolism , 2004, Cancer science.

[20]  D. Carter.  TNM Classification of Malignant Tumors , 1998 .

[21]  H. Ishitsuka,et al.  Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  S K Carter,et al.  Calibrated phase II clinical trials in oncology. , 1986, Statistics in medicine.

[23]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[24]  E. Nakakura,et al.  Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

[25]  A. Krasinskas,et al.  Assessing treatment effect in pancreatic cancer. , 2012, Archives of pathology & laboratory medicine.

[26]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.